NCT07649551Not yet recruiting
Optimizing Implementation of Long Acting Injectable PrEP
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
Our goal is to optimize LAI-PrEP implementation within the context of other PrEP methods. Our strategy is flexible to allow pivot to include forthcoming PrEP dosing options should they become available
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 29 May 2026
- Start date
- 1 Jan 2027
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- University of Minnesota
- Diseases
- HIV
- NCT number
- NCT07649551
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 1 Jan 2027 to the primary completion date, 31 Dec 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Provider/staff inclusion criteria:
- 18 years of age or older,
- affiliated with a participating clinic, and
- be involved in prescribing or supporting PrEP care delivery.
- Provider/staff exclusion criteria:
- 17 years of age or younger,
- not affiliated with a participating clinic, and
- not involved in prescribing or supporting PrEP care delivery.
- De-identified electronic medical record review inclusion criteria:
- 16 years of age or older, and
- had a clinical visit for any form of PrEP care during the study period at a participating clinic site.
- De-identified electronic medical record review exclusion criteria:
- 15 years of age or younger, and
- no clinical visit for any form of PrEP care during the study period at a participating clinic site.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.